01
Balancing the skin's microbial ecosystem
Balancing the skin microbiome to protect skin immunity and the barrier.
05 / K-ECO BIO 10 · PIPELINE
Bio-food for skin cells,
and nature-based drug candidates
GRBM MCM is a Microbiome BIO Cosmetic in which the metabolome itself is the body of the product; GRBM MHM-PI is a natural-product drug-candidate platform developed from the GRBM library and AI omics. Together they create fast, high-margin revenue and long-term option value.
In plain words
I see cosmetics as "bio-food for skin cells". GRBM MCM does not add a little plant extract to a basic cosmetic base. Most of the product is plant metabolome liquid, and only a small amount of basic cosmetic material is mixed in. The metabolome itself becomes the body of the cosmetic — a shift in the cosmetic-manufacturing paradigm.
GRBM MHM-PI is a natural-product drug-candidate material platform developed by combining the GRBM library and smart-farm-based ecological resources through AI omics. It runs from biodiversity → large-scale data on metabolites and genetic material → AI-based candidate discovery → pre-clinical and clinical verification.
MCM, with a shorter development time and a lighter regulatory burden than medicines, creates fast, high-margin revenue; MHM-PI creates long-term option value through platform IP and synergy with Healthcare 4.0. The two tracks are managed strictly apart.
GRBM MCM · MEDI-CARE COSMETIC
From "extract cosmetics"
to "metabolome cosmetics"
| Existing plant-extract cosmetics | Plant-metabolome BIO Cosmetic (GRBM MCM) | |
|---|---|---|
| Composition | A little plant extract blended into a base such as cream, emulsion or serum | Mostly plant metabolome liquid, with only a small amount of base material |
| Function | Limited, with extract variability and instability | Metabolism-based bioactive components are the body |
| Meaning | Extract-added cosmetic | The metabolome itself is the body of the cosmetic |
The cosmetics market has grown along innovation axes such as plant extracts, probiotics and organic cosmetics. Microbiome BIO Cosmetic embraces these categories and goes beyond them. It is not just "natural cosmetics" but a bio-cosmetic that redesigns the skin ecosystem (eco-biology).
02
Recovery of basal skin cells
Metabolome-based function aimed at recovery and regeneration of basal skin cells.
03
Barrier strengthening and soothing
Raises barrier stability; suited to sensitive and trouble-prone skin.
04
Metabolism-based bioactive components
Anti-inflammatory and antioxidant metabolites work on skin ageing and damage recovery.
NATURAL BEAUTY 2.0
From the gut to the skin —
integrated Inside–Out beauty
The GRBM platform already has inner-care and inner-beauty lines in GRBM, PANAX GRBM and GRBM MFK. Adding GRBM MCM opens a new market that existing K-Beauty has not offered: "a metabolism-based integrated beauty platform".
- Gut microbes → skin microbesCaring for the ecosystem inside the body and the one on the skin together
- Metabolic recovery → barrier recoveryOrder in metabolism leads to recovery of the barrier
- Inner-beauty nutrition → basal-cell regenerationThe metabolome you eat becomes material for basal skin cells
- Plant-metabolome nutrition → skin metabolic recoveryPlant metabolomes become the basis of skin metabolism
The flagship Skin Barrier Ritual Set consists of three bath products, one body mist and one liquid soap. One 50 ml bottle of bath product goes into the tub for a 20-minute bath, recommended once every five days. The body mist is sprayed on towel-dried skin after a shower and patted in, and the liquid soap, a plant-based alcohol-free base with the GRBM fleabane formula, is a daily body cleanser the whole family can use.
| Positioning | Core |
|---|---|
| Cell Recovery Cosmeceutical | Basal-cell recovery, barrier stability, regeneration of damaged skin, anti-inflammatory and antioxidant metabolome-based function |
| Microbiome BIO Cosmetic | Skin microbial balance, stronger skin immunity and barrier, optimized for sensitive and trouble-prone skin |
| K-Beauty global scalability | The credibility of Korean cosmetics + GRBM technology, a premium brand strategy, global distribution including OEM/ODM |
- High-Margin, Fast-to-MarketShorter development than medicines and a premium pricing strategy favour early revenue
- Platform scalabilityNot one product but dozens of functional bio-cosmetics
- OEM/ODM collaborationCombining with Korea's cosmetics manufacturing ecosystem enables fast global expansion
- K-Beauty × BioTechK-Beauty's sensibility and branding meet GRBM's science and metabolic technology
- Low regulatory barriersA lighter regulatory burden than medicines enables fast commercialization and early returns
Drug candidates that take biodiversity
and metabolic networks as their core resource
Instead of chasing a single molecular target, candidates are found in plant–microbe metabolic networks. A nature-based bio-material for the AI era.
GRBM MHM-PI · PHARMACEUTICAL INGREDIENT
Natural-product drug candidates
found with AI omics
Unlike traditional protein therapeutics that chase a single molecular target, GRBM MHM-PI takes the ecological metabolic network (plant–microbe metabolome) as its starting point for candidate discovery. For investors, this line is a strategic asset that offers platform IP, long-term option value and synergy with Healthcare 4.0.
01
A platform-based approach
Finds candidates targeting complex metabolic pathways within plant–microbe metabolic networks.
02
AI omics capability
Integrates tens of thousands of genetic-material and metabolite patterns with AI to predict candidate combinations.
03
Biodiversity-based IP
Each plant's unique Vital Probiotics and metabolic profile is core IP protectable through reproducible fractionation and combination techniques.
04
Lower safety and misuse risk
Nature-based fractions carry lower risks of genetic manipulation and over-activation, an advantage in genetic safety.
- An omics data hubIntegrates genome, transcriptome, metagenome and metabolome data to build "ecological metabolic signatures"
- AI candidate discoveryMachine-learning and graph-based models predict key nodes and combinations in metabolic networks, with in-silico safety and pharmacology predictions first
- Ecological metabolic realignmentNot suppressing a single target, but inducing cellular and tissue balance through the realignment of metabolic networks
- Data → experiment → clinic loopAI predictions are reinforced by pre-clinical validation, and clinical data retrains the model to sharpen candidates
QUALITY · DEVELOPMENT PATHWAY
A five-level quality system
and a step-by-step roadmap
Manufacturing and quality control
Plants grown in smart farms with specially managed ecological environments secure the consistency and traceability of raw materials. High-purity fractionation and impurity removal are designed to make even high-purity injectable-grade materials possible, and formulations — from injectables to transdermal and oral forms — are prioritized while evaluating regulation, safety and commercial potential for each route.
-
01
Raw material
Smart-farm-based raw-material management
-
02
Metabolic induction
The VPMI metabolic process
-
03
Fractionation
Separating target component groups
-
04
Purification
High-purity refinement and impurity removal
-
05
GMP-grade finished product
The final grade, premised on an approval pathway
A step-by-step development roadmap
-
01
Candidate discovery
AI-based candidate discovery and in-vitro screening
-
02
Pre-clinical
Animal pre-clinical safety and pharmacology
-
03
Process and toxicity
Establishing the GMP production process and toxicity studies
-
04
Early clinical
Phase 1 and 2 design and regulatory consultation
-
05
Approval and commercialization
Indication-specific late-stage trials, approval and commercialization
For the trust of investors and regulators, we keep to regulatory conservatism: every efficacy claim is backed by pre-clinical and clinical data. Indications are prioritized in areas that can be validated in pre-clinical models and have large unmet needs, such as inflammatory bowel disease, microbiome-linked diseases, circulatory disorders, metabolic and other inflammatory diseases, and adjunctive regenerative medicine.
Read moreCloseIP and moat, commercial pathways, risks and responses, and an example QL5 candidate
IP and competitive moat
- Platform IPMetabolic-fraction combination methods, Vital Probiotics matching algorithms, fraction purification processes and AI candidate-prediction models can be protected in layers
- Source-resource advantageTraceable biodiversity resources secured in smart farms are an asset that cannot easily be copied
- Advantages against riskLower ethical and immunogenicity risk than synthetic protein drugs, and limited potential for misuse
- Diverse commercial pathwaysEarly value through licence-out, co-development and patent-based technology transfer; in the mid to long term, high-value commercialization through own clinical trials and approval
Converging food and medicine, and Healthcare 4.0
MHM-PI is a pipeline that can move into medical nutrition, adjunctive care and drug candidates, covering everything from daily health care to the management of serious disease. Combined with digital health, remote monitoring and personalized data, it can offer metabolic-realignment solutions at the stages of prevention, serious-disease management and recovery.
Risks and responses
| Risk | Detail | Response |
|---|---|---|
| Scientific validation | AI predictions are supporting evidence; experimental validation is essential | Allocate sufficient budget to pre-clinical and clinical design |
| Regulation | Natural-product drug regulation differs by country | Choose early target countries and begin regulatory consultation early |
| Production and quality | Ecological raw materials vary | Smart-farm standardization and five-level quality control |
| Commercialization | Clinical stages are costly | Spread the funding burden through staged licensing and partnerships |
An example candidate — QL5 Songi Precision Injectable Candidate
A high-level bio-candidate material made from matsutake GRBM × Lactobacillus plantarum sp. × QL5 purification. Its core bioactive components are bacteriocins, External miRNA and short-chain fatty acids (SCFAs), and it points to precision-bio research directions such as long-residence bio-signals based on exogenous miRNA, research into cell-membrane and DNA stability and telomere health, and exploration of the potential to extend healthy lifespan. Other candidates — precision extracts, fractions A and B, mucosal delivery sprays and oral capsules — are at the research and pre-clinical screening stage.
GRBM MHM-PI candidate materials are research and professional candidate materials; they are not registered as medicines, medical devices or health functional foods and are not intended to diagnose, treat or prevent disease. Pharmaceutical application presupposes separate non-clinical, clinical, GMP and approval procedures.
PARTNERSHIP · INVESTMENT
The world's first true eco-bio platform technology —
we are looking for the one partner
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.